EQONEX LTD (EQOS) Fundamental Analysis & Valuation

NASDAQ:EQOSSGXZ53262598

Current stock price

0.0931 USD
-0.05 (-33.88%)
At close:
0.0869 USD
-0.01 (-6.66%)
After Hours:

This EQOS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EQOS Profitability Analysis

1.1 Basic Checks

  • EQOS had negative earnings in the past year.
  • In the past year EQOS has reported a negative cash flow from operations.
EQOS Yearly Net Income VS EBIT VS OCF VS FCFEQOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -122.39%, EQOS is doing worse than 98.06% of the companies in the same industry.
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EQOS Yearly ROA, ROE, ROICEQOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -500 -1K -1.5K

1.3 Margins

  • EQOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQOS Yearly Profit, Operating, Gross MarginsEQOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 1K -1K

3

2. EQOS Health Analysis

2.1 Basic Checks

  • EQOS has more shares outstanding than it did 1 year ago.
  • EQOS has a worse debt/assets ratio than last year.
EQOS Yearly Shares OutstandingEQOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
EQOS Yearly Total Debt VS Total AssetsEQOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -11.66, we must say that EQOS is in the distress zone and has some risk of bankruptcy.
  • EQOS has a Altman-Z score of -11.66. This is in the better half of the industry: EQOS outperforms 76.21% of its industry peers.
  • EQOS has a Debt/Equity ratio of 1.65. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of EQOS (1.65) is worse than 82.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Altman-Z -11.66
ROIC/WACCN/A
WACCN/A
EQOS Yearly LT Debt VS Equity VS FCFEQOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 1.08 indicates that EQOS should not have too much problems paying its short term obligations.
  • EQOS has a Current ratio of 1.08. This is amongst the best in the industry. EQOS outperforms 80.58% of its industry peers.
  • EQOS has a Quick Ratio of 1.08. This is a normal value and indicates that EQOS is financially healthy and should not expect problems in meeting its short term obligations.
  • EQOS has a better Quick ratio (1.08) than 81.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
EQOS Yearly Current Assets VS Current LiabilitesEQOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

6

3. EQOS Growth Analysis

3.1 Past

  • EQOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1533.22%.
  • EQOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 1741.83%.
  • Measured over the past years, EQOS shows a very strong growth in Revenue. The Revenue has been growing by 77.30% on average per year.
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.42% on average over the next years. This is quite good.
  • EQOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.26% yearly.
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EQOS Yearly Revenue VS EstimatesEQOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
EQOS Yearly EPS VS EstimatesEQOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

1

4. EQOS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EQOS. In the last year negative earnings were reported.
  • Also next year EQOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQOS Price Earnings VS Forward Price EarningsEQOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQOS Per share dataEQOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EQOS's earnings are expected to grow with 25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.05%
EPS Next 3Y25.6%

0

5. EQOS Dividend Analysis

5.1 Amount

  • No dividends for EQOS!.
Industry RankSector Rank
Dividend Yield N/A

EQOS Fundamentals: All Metrics, Ratios and Statistics

EQONEX LTD

NASDAQ:EQOS (11/29/2022, 8:00:01 PM)

After market: 0.0869 -0.01 (-6.66%)

0.0931

-0.05 (-33.88%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)09-06
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.31M
Revenue(TTM)5.29M
Net Income(TTM)-75.00M
Analysts45.71
Price Target5.36 (5657.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z -11.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%
EBIT growth 1Y-4878.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.84%
EBIT Next 3Y48.54%
EBIT Next 5Y50.96%
FCF growth 1Y-4716.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3996.89%
OCF growth 3YN/A
OCF growth 5YN/A

EQONEX LTD / EQOS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EQONEX LTD (EQOS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to EQOS.


Can you provide the valuation status for EQONEX LTD?

ChartMill assigns a valuation rating of 1 / 10 to EQONEX LTD (EQOS). This can be considered as Overvalued.


What is the profitability of EQOS stock?

EQONEX LTD (EQOS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for EQONEX LTD?

The Earnings per Share (EPS) of EQONEX LTD (EQOS) is expected to grow by 63.76% in the next year.